Working… Menu
Trial record 34 of 163 for:    ISOTRETINOIN

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00038376
Recruitment Status : Completed
First Posted : May 31, 2002
Last Update Posted : October 29, 2018
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Condition or disease Intervention/treatment Phase
Lymphoma, T-Cell Mycosis Fungoides Hematologic Neoplasms Drug: Isotretinoin (Accutane) Drug: Interferon Alpha Phase 2

Detailed Description:

Retinoids have shown activity in T-cell malignancies in past studies (both isotretinoin and etretinate) with an overall response rate of about 60%. One third of those responses were complete responses. Interferon-alpha has proven efficacy in wide ranges of human malignancies including T-cell lymphomas as a single agent. A clinical trial was needed to evaluate the response rate of these two agents combined.

Interferon is a normal body protein, which is made by cells after exposure to viruses. It acts as a messenger to warn surrounding cells of invasions by viruses and, possibly, by cancer cells. Isotretinoin is a synthetic form of Vitamin A which effects the growth of normal cells and cancer cells.

Participants participating in this study will receive a combination of alpha-interferon and isotretinoin. Alpha-interferon will be given once a day for an initial period of 12 weeks. Participants will take the drug home, where a nurse or family member of the participant (who can be trained at UTMDACC) will inject it just under the skin (SQ). Isotretinoin will be given by mouth twice a day.

If a participant's disease does not show a response, the alpha-interferon and the isotretinoin will be increased. If side effects occur, the dose of alpha-interferon and/or isotretinoin will be decreased by 50%. If the side effects are severe, therapy will be discontinued. If the participant's disease is unresponsive or worsens, the participant will be taken off study and other treatments will be recommended.

Responding participants will be placed on a maintenance schedule for as long as they respond. Up to 60 participants will be studied at UT M.D. Anderson Cancer Center to test the effectiveness of this drug combination.

This is an investigational study. Alpha-interferon and isotretinoin are FDA approved and commercially available.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies
Actual Study Start Date : May 8, 1990
Actual Primary Completion Date : June 30, 2005
Actual Study Completion Date : June 30, 2005

Arm Intervention/treatment
Experimental: 1
Alpha-interferon + Isotretinoin
Drug: Isotretinoin (Accutane)
0.5 mg/k (1.0 mg/k total) by mouth twice a day
Other Name: 13-cis-Retinoic Acid

Drug: Interferon Alpha
Starting dose of 3 MU injected under skin once a day for 12 weeks.
Other Names:
  • Intron A
  • Interferon alfa-2b

Primary Outcome Measures :
  1. To determine if the drug combination of alpha-interferon and isotretinoin is effective in controlling T-cell malignancies. [ Time Frame: 15 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with histologic proof of incurable T-cell malignancy or Hodgkin's disease, and not eligible for existing/higher priority protocols. Patients with Hodgkin's disease will be eligible only if they have failed at least a MOPP-like and ABVD-like regimen.
  2. Patients should not have received chemotherapy, immunotherapy, hormonal therapy, or radiation therapy within three weeks of entry into the study and must have recovered from acute toxic effects of prior therapy.
  3. Patients must have a life expectancy of at least 12 weeks and a performance status of less than or equal to 2 (Zubrod scale: Appendix A).
  4. Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with policies of the hospital. The only approved consent form is appended to this protocol.
  5. Patients must have measurable or evaluable disease.
  6. Patients must be greater than or equal to 18 years old.
  7. Patients may receive no other concurrent chemotherapy, immunotherapy, or radiotherapy.
  8. Patients should have adequate hepatic function with bilirubin of less than or equal to 2.0 mg%, and SGPT of less than or equal to 4 times the upper limits of normal.
  9. Patients should have adequate renal function (defined as serum creatinine of less than or equal to 2.0 mg%).
  10. Patients should have serum triglyceride level less than or equal to 2.5 times the upper limits of normal.
  11. Patients may not have serious intercurrent medical illness.
  12. Patients of child bearing potential must be practicing adequate contraception.
  13. Patients will be eligible regardless of the extent of prior chemotherapy.

Exclusion Criteria:

1) Pediatric Patients under 18 years old.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00038376

Layout table for location information
United States, Texas
M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Layout table for investigator information
Principal Investigator: Razelle Kurzrock, MD, BS UT MD Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00038376     History of Changes
Other Study ID Numbers: DM90-007
First Posted: May 31, 2002    Key Record Dates
Last Update Posted: October 29, 2018
Last Verified: October 2018
Keywords provided by M.D. Anderson Cancer Center:
T-cell lymphoma
mycosis fungoides
T-cell malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycosis Fungoides
Hematologic Neoplasms
Lymphoma, T-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, T-Cell, Cutaneous
Lymphoma, Non-Hodgkin
Neoplasms by Site
Hematologic Diseases
Interferon alpha-2
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents